Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...
Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...
Japan’s drug pricing scheme has gotten more complicated, and pharma companies should brace themselves for annual price cuts.
A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...
1d
HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...
Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Latest data shows the largest indicative borrow rate increases among liquid option names include: Veru (VERU) 2.09% +0.85, NovaDel Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback